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hel lenic- journal-of-cardiology/EDITOR’S PAGEPulmonary arterial hypertension and quality of
life in cardiology. Do we really need more
studies?Cardiovascular medicine has significantly evolved over the
past three decades, as reflected by the decreasing inci-
dence of morbidity and mortality from myocardial in-
fractions and in the successful identification and
modification of a series of cardiovascular risk factors.1e5
Significant accomplishments have also been achieved in
understanding the diagnosis and treatment of pulmonary
hypertension, especially pulmonary arterial hypertension,
with the introduction of medicines in the clinical practice
capable of modifying symptoms and the physical history of
the disease.6,7 These achievements have oriented research
toward the improvement of the patient’s status and quality
of life. To this end, several studies have identified super-
vised exercise rehabilitation as capable of increasing
functional capacity and quality of life.8,9 However, these
studies are based on small sample sizes, and we are un-
aware of the specific rehabilitation practices that may
achieve the most significant and valuable improvements.
Interestingly, in this issue of Hellenic J Cardiol, Laoutaris ID
et al.10 present the results of supervised inspiratory muscle
training in the functional status and life quality of patients
with pulmonary hypertension. According to this pilot study,
high-intensity inspiratory muscle training may improve
dyspnea, exercise capacity and quality of life, emphasizing
the need for a holistic approach to managing this high-risk
group of patients.
However, pulmonary arterial hypertension, especially in
adults with congenital heart disease, remains relatively
rare and is difficult for inexperienced physicians to manage
(Table 1). These issues are elucidated by Giannakoulas G
and Gatzoulis MA in the recent issue of Hell J Cardiol (9).
These researchers propose the question of “whether the
patients must be treated according to established guide-
lines or with more aggressive protocols by specializedPeer review under responsibility of Hellenic Cardiological
Society.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).physicians in tertiary centers”.11 Finally, the authors note
the need to further research this group of patients, espe-
cially patients with Eisenmenger syndrome, in tertiary
centers in collaboration with pulmonary arterial hyperten-
sion and adult congenital heart disease specialists.
Another interesting topic discussed in this issue of Hellenic
J of Cardiol is the Health Related Quality of Life in patients
with coronary artery disease after coronary revasculariza-
tion. Several studies have agreed on the superiority of
revascularization over medicine treatment alone, especially
in symptom relief, but also in survival.12,13 Moreover, a series
of scores have been introduced to select patients appropriate
for coronary artery stenting or coronary artery by-pass
grafting.14,15 Nevertheless, the issue of Health Related
Quality of Life after coronary artery stenting or coronary ar-
tery by-pass grafting has not been extensively addressed.
Takousi M et al. have analyzed data from 34 publications
involving 15,992 patients undergoing either type of revascu-
larization to conclusively address this topic. Interestingly
these researchers found that both types of revascularization
may improve patient Health Related Quality of Life, an issue
that may be of importance when patients are informed to
decide whether to comply with medical management or to
choose a revascularization procedure.16 Taken together,
these findings suggest that both the treatment of pulmonary
arterial hypertension and the improvement in quality of the
life after a cardiovascular event remain unresolved issues and
further studies are needed.
Two interesting studies from the region of Crete further
extend our knowledge concerning the quality of treatment in
the management of patients with arrhythmias. Implantable
cardioverter defibrillators (ICDs) have been established as
the gold standard treatment for themanagement of patients
with ventricular tachycardia.17 However, patients with ICDs
followed up for a long-term period present a significant
number of complications. Therefore, real world data
regarding the identification of patients most suitable for ICD
therapy is of importance. According to this long termElsevier B.V. This is an open access article under the CC BY-NC-ND




The first molecule of its class.
Dual endothelin receptor type A and B
antagonist
In patients at WHO-FC II, III or IV
Ambrisertan Administration PO.
Selective antagonists of endothelin receptor
type A.
In patients at WHO-FC II, III or IV
Macitentan Administration PO.
Newer Dual endothelin receptor type A and B
antagonist with fewer side effects
In patients at WHO-FC II, III or IV
Phosphodiesterase type 5 inhibitors
(enhance the NOecGMP pathway, slowing cGMP
degradation)
Sildenafil Administration PO. t.i.d
The first molecule of its class
In patients at WHO-FC II, III or IV
Tadalafil Administration PO. Once daily
In patients at WHO-FC II, III or IV
Vardenafil Administration PO. b.i.d
In patients at WHO-FC II, III or IV
Guanylate cyclase stimulators
(enhance cGMP production)
Riociguat Administration PO t.i.d
The only molecule of its category
It cannot be combined with
Phosphodiesterase type 5 inhibitors
In patients at WHO-FC II, III or IV
Prostacyclin analogues
Epoprostenol Administration IV. Short half-life (3e5 min) it
requires
cooling and continuous administration
In patients at WHO-FC III or IV
Iloprost Administration inhaled 6e8 times per day
In patients at WHO-FC III or IV
Treprostinil Administration mainly SC or IV
In patients at WHO-FC III or IV
Beraprost Administration PO
Novel agent




In patients at WHO-FC III
216 Editor’s pageregistry18 (21 years) the frequency of complications is rela-
tively low (approximately 15%), while appropriate ICD ther-
apies were more frequent in patients selected for secondary
prevention. In addition, the time for the first appropriate
therapy was longer in patients selected for primary pre-
vention highlighting the need to extend the follow up period
to make conclusions about the absolute beneficial effect of
ICD therapy. Concerning atrial arrhythmias there is consis-
tent data from the past several years that new oralanticoagulants (NOAC) have a safer profile in patients with
non-valvular atrial fibrillation.19e21 However, as Papakon-
stantinou et al. observed,22 based on data from the emer-
gency department of a health center in southern Greece, the
implementation of NOACs is low, despite evidence from the
Danish registry showing a decline in the initiation of warfarin
among oral anticoagulation-naı¨ve atrial fibrillation pa-
tients.23 Possible reasons for these inconsistencies may be
the unwillingness of patients on previously established
vitamin K antagonist therapies to convert to newer treat-
ments, as well as the cost of NOACs.
Concerning coronary artery disease (CAD) management
and interventional procedures significant data are dis-
cussed in the review article of Hahalis G et al.24 Although
the radial artery approach has been established as prefer-
ential over the femoral arterial access site in many cen-
ters,25 especially due to the lower rates of complications
and patient preferences, the ulnar artery is most often
considered in cases in which the radial artery approach is
unsuccessful. However, as the authors emphasize once
arterial access is obtained the likelihood of a successful
coronary procedure is similar between the two forearm
arteries. Accordingly, based on a review of the literature
the authors conclude on the need for radial operators to
extend their skills and to adopt ulnar artery access as a
reasonable alternative in patients with unfavorable femoral
and radial artery characteristics. Despite the significant
improvements in interventional procedures, concerns
remain regarding the prevalence of high platelet reactivity
due to aspirin and clopidogrel resistance. Nevertheless,
based on previous reports and on data presented in this
issue from Dusan AD et al. there is no straight-forward as-
sociation between high platelet reactivity and cardiovas-
cular events.26e28 Moreover, cardiometabolic risk profile
has been identified as a factor associated with high platelet
reactivity that may shed light on previous reports between
the association of platelet reactivity and arterial wall
properties.29
References
1. Panagiotakos DB, Georgousopoulou EN, Fitzgerald AP,
Pitsavos C, Stefanadis C. Validation of the HellenicSCORE (a
Calibration of the ESC SCORE Project) regarding 10-year risk of
fatal cardiovascular disease in Greece. Hellenic J Cardiol.
2015;56:302e308.
2. Chrysohoou C. Are Cardiac Risk Scores useful in daily clinical
practice? Hellenic J Cardiol. 2015;56:309e310.
3. Aissaoui N, Puymirat E, Juilliere Y, et al. Fifteen-year trends in
the management of cardiogenic shock and associated 1-year
mortality in elderly patients with acute myocardial infarc-
tion: the FAST-MI programme. Eur J Heart Fail. 2016;18:
1144e1152.
4. Foussas S. Acute coronary syndromes and comorbidities. Hel-
lenic J Cardiol. 2015;56:351e354.
5. Castro-Torres Y, Katholi RE, Yar Khan N. Aspirin for primary
prevention of cardiovascular diseases: current concepts,
unanswered questions and future directions. Hellenic J Car-
diol. 2015;56:461e474.
6. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guide-
lines for the diagnosis and treatment of pulmonary hyperten-
sion: The Joint Task Force for the Diagnosis and Treatment of
Pulmonary Hypertension of the European Society of Cardiology
Editor’s page 217(ESC) and the European Respiratory Society (ERS): Endorsed by:
Association for European Paediatric and Congenital Cardiology
(AEPC), International Society for Heart and Lung Trans-
plantation (ISHLT). Eur Heart J. 2016;37:67e119.
7. Vlachogeorgos GS, Daskalopoulos N, Blatsiotis P, Kourbeti IS,
Mantas I, Stathopoulos GT. Bosentan for patients with echo-
cardiographic evidence of pulmonary hypertension due to long-
standing rheumatic mitral stenosis. Hellenic J Cardiol. 2015;
56:36e43.
8. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respira-
tory training improve exercise capacity and quality of life in
patients with severe chronic pulmonary hypertension. Circu-
lation. 2006;114:1482e1489.
9. de Man FS, Handoko ML, Groepenhoff H, et al. Effects of ex-
ercise training in patients with idiopathic pulmonary arterial
hypertension. Eur Respir J. 2009;34:669e675.
10. Laoutaris ID, Dritsas A, Kariofyllis P, Manginas A. Benefits of
inspiratory muscle training in patients with pulmonary hyper-
tension: a pilot study. Hellenic J Cardiol. 2016;57(4).
11. Giannakoulas G, Gatzoulis MA. Pulmonary arterial hypertension
in congenital heart disease: current perspectives and future
challenges. Hellenic J Cardiol. 2016;57(4).
12. De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-
guided PCI versus medical therapy in stable coronary disease.
N Engl J Med. 2012;367:991e1001.
13. Authors/Task Force m, Windecker S, Kolh P, et al. 2014 ESC/
EACTS Guidelines on myocardial revascularization: The Task
Force on Myocardial Revascularization of the European Society
of Cardiology (ESC) and the European Association for Cardio-
Thoracic Surgery (EACTS)Developed with the special contri-
bution of the European Association of Percutaneous Cardio-
vascular Interventions (EAPCI). Eur Heart J. 2014;35:
2541e2619.
14. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery
bypass graft surgery versus percutaneous coronary interven-
tion in patients with three-vessel disease and left main coro-
nary disease: 5-year follow-up of the randomised, clinical
SYNTAX trial. Lancet. 2013;381:629e638.
15. Hickey GL, Grant SW, Murphy GJ, et al. Dynamic trends in
cardiac surgery: why the logistic EuroSCORE is no longer suit-
able for contemporary cardiac surgery and implications for
future risk models. Eur J Cardiothorac Surg. 2013;43:
1146e1152.
16. Takousi MG, Schmeer S, Manaras I, Olympios CD, Makos G,
Troop NA. Health Related Quality of Life after Coronary
Revascularization: a systematic review with meta-analysis.
Hellenic J Cardiol. 2016;57(4).
17. Priori SG, Blomstrom-Lundqvist C. 2015 European Society of
Cardiology Guidelines for the management of patients with
ventricular arrhythmias and the prevention of sudden cardiac
death summarized by co-chairs. Eur Heart J. 2015;36:
2757e2759.
18. Kanoupakis EM, Fanourgiakis JA, Mavrakis HE, et al. Long term
clinical outcome of implantable cardioverter defibrillator re-
cipients in the island of Crete. Hellenic J Cardiol. 2016;57(4).
19. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for
the management of atrial fibrillation developed in collabora-
tion with EACTS: The Task Force for the management of atrial
fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart
Rhythm Association (EHRA) of the ESCEndorsed by the Euro-
pean Stroke Organisation (ESO). Eur Heart J. 2016. http://dx.
doi.org/10.1093/eurheartj/ehw210.
20. Vardas P, Andrikopoulos G, Baroutsou B, Investigators O. A
Greek prospective observational study of cardiovascular
morbidity and mortality in patients with atrial fibrillation.
Hellenic J Cardiol. 2015;56:475e494.
21. Kalinderi K, Fragakis N, Koskinas KC, et al. Association between
rs2200733 polymorphism on chromosome 4q25 and atrial
fibrillation in a Greek population. Hellenic J Cardiol. 2015;56:
224e229.
22. Papakonstantinou PE, Asimakopoulou NI, Gargeraki A,
Gaitanis KS, Mintzaridis E. Anticoagulation management in
non-valvular atrial fibrillation in rural and remote Crete. A
single-center study from the region of Sitia. Hellenic J Cardiol.
2016;57(4).
23. Olesen JB, Sorensen R, Hansen ML, et al. Non-vitamin K
antagonist oral anticoagulation agents in anticoagulant naive
atrial fibrillation patients: Danish nationwide descriptive data
2011e2013. Europace. 2015;17:187e193.
24. Hahalis G, Deftereos S, Bertrand OF. Is Ulnar artery the Ulysses
Ultimate Resort for Coronary Procedures? Hellenic J Cardiol.
2016;57(4).
25. Patsilinakos S, Tsinivizov P, Papadakis E, Kyriakopoulos V,
Marinos S, Poulimenos L. Left internal mammary arterial
angiography via the right radial approach: description of
technique, single-centre experience, and brief review of the
literature. Hellenic J Cardiol. 2015;56:522e526.
26. Siasos G, Mourouzis K, Oikonomou E, et al. Duration of dual
antiplatelet therapy after coronary stenting. Curr Pharm Des.
2016. PMID: 27510478.
27. Siasos G, Oikonomou E, Zaromitidou M, et al. Clopidogrel
response variability is associated with endothelial dysfunction
in coronary artery disease patients receiving dual antiplatelet
therapy. Atherosclerosis. 2015;242:102e108.
28. Avramovic D, Dusan AD, Vladan K, et al. Prevalence of high on-
treatment platelet reactivity in patients after percutaneous
coronary intervention. Hellenic J Cardiol. 2016;57(4).
29. Siasos G, Zaromitidou M, Oikonomou E, et al. Effects of
CYP2C19 polymorphism on endothelial function, arterial stiff-
ness and inflammation in coronary artery disease patients
under clopidogrel treatment. Curr Pharm Des. 2015;21:
5041e5046.
Dimitris Tousoulis, MD, PhD *
1st Cardiology Department,
Athens University Medical School,
Hippokration Hospital, Athens, Greece*Prof. Dimitris Tousoulis, MD, PhD, FESC, FACC, Vasilissis
Sofias 114, TK 115 28, Hippokration Hospital, Athens,
Greece. Tel.: þ30 213 2088099; fax þ30 213 2088676.
E-mail address: drtousoulis@hotmail.com
Available online 17 September 2016
